Skip to main content

Advertisement

Table 4 Construct validity of clinical tools for assessing localized scleroderma with Skindex-29 subscales

From: Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) adapted for use in adult patients: report from an initial validation study

  Skindex-29: emotions Skindex-29: symptoms Skindex-29: functioning
rs p rs p rs p
mLoSSI −0.05 0.76 −0.20 0.21 0.09 0.6
PhysGA-A −0.13 0.44 0.04 0.81 0.07 0.65
PtGA-S 0.16 0.33 0.27 0.33 0.24 0.14
LoSDI 0.12 0.45 0.02 0.93 0.15 0.36
PhysGA-D 0.32 0.04 0.44 < 0.01 0.37 0.02
PtGA-D 0.4 < 0.01 0.48 < 0.01 0.38 < 0.01
  1. mLoSSI modified Localized Scleroderma Skin Severity Index, PhysGA-A physician global assessment of disease activity, PtGA-S patient global assessment of disease severity, LoSDI Localized Scleroderma Damage Index, PhysGA-D physician global assessment of disease damage, PtGA-D patient global assessment of disease damage, rs Spearman’s rank correlation coefficient, p p-value